Comparison of 10 noninvasive models for predicting overall survival in patients with intermediate-stage hepatocellular carcinoma

被引:4
|
作者
Hsu, Wei-Fan [1 ,2 ,3 ,9 ]
Chang, Kai-Chih [1 ]
Chen, Te-Hong [4 ,9 ]
Lin, Chien-Hung [5 ,9 ]
Lin, Ying-Chun [6 ,9 ]
Tsai, Ming-Hung [7 ,9 ]
Chen, Pei-Yu [8 ,9 ]
Wang, Hung-Wei [1 ,3 ,9 ]
Chu, Chia-Sheng [1 ,9 ]
Peng, Cheng-Yuan [1 ,3 ,9 ]
机构
[1] China Med Univ Hosp, Ctr Digest Med, Dept Internal Med, 2 Der Yuh Rd, Taichung 40447, Taiwan
[2] China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan
[3] China Med Univ, Sch Med, Taichung, Taiwan
[4] China Med Univ Hosp, Dept Surg, Taichung, Taiwan
[5] China Med Univ Hosp, Dept Radiol, Taichung, Taiwan
[6] China Med Univ Hosp, Dept Radiat Oncol, Taichung, Taiwan
[7] China Med Univ Hosp, Div Hematol & Oncol, Dept Internal Med, Taichung, Taiwan
[8] China Med Univ Hosp, Dept Pathol, Taichung, Taiwan
[9] China Med Univ Hosp, Liver Canc Team, Taichung, Taiwan
关键词
albumin-bilirubin (ALBI) grade; intermediate-stage hepatocellular carcinoma; Lok grade; noninvasive model; SIGNIFICANT FIBROSIS; LIVER-FUNCTION; HEPATITIS-B; CIRRHOSIS; INDEX; ALBI; SUBCLASSIFICATION; CRITERIA; PROPOSAL; DISEASE;
D O I
10.1097/MD.0000000000027000
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Intermediate-stage hepatocellular carcinoma (HCC) is heterogeneous in terms of tumor size, number, and effects on liver function. Various noninvasive models have been proposed to assess functional hepatic reserve or fibrosis severity in patients with HCC. This study assessed the feasibility of 10 noninvasive models and compared their prognostic ability for patients with intermediate-stage HCC. This study retrospectively enrolled 493 patients with intermediate-stage HCC who received treatment at China Medical University Hospital from January 2012 to November 2018. Demographic data, clinical features, and factors associated with overall survival (OS) were recorded at baseline. Receiver-operating characteristic curve analysis and the DeLong method were respectively employed to evaluate and compare the models' OS prediction performance. Of the 493 patients, 373 (75.7%) were male, and 275 (55.8%) had liver cirrhosis (LC). The median age was 64 years (interquartile range: 55-72). Most patients had tumor volume <= 50% (n = 424, 86.0%), and the maximum tumor size was 6.0 (4.0-8.5) cm. The median alpha-fetoprotein was 36.25 (6.13-552.91) ng/mL. The patients underwent transarterial chemoembolization (TACE, n = 349) or surgery (n = 144). The median follow-up period was 26.07 (9.77-48.27) months. Across the 10 models, the albumin-bilirubin (ALBI) score had the highest area under the receiver operating characteristic curve (AUROC) (0.644, 95% confidence interval: 0.595-0.693) in all patients. In subgroup analyses, the Lok index, platelet-albumin-bilirubin score, ALBI score, and Lok index had the highest AUROC values in patients without cirrhosis, with cirrhosis, undergoing TACE, and undergoing surgery, respectively. Multivariate Cox regression analysis revealed that independent predictors of longer OS were ALBI grade 1 in all patients, patients with LC, and patients undergoing TACE and Lok index grade 1 in patients without LC and patients undergoing surgery. Among the 10 noninvasive models, ALBI score exhibited the highest diagnostic value in predicting OS for all patients, patients with cirrhosis, and those undergoing TACE, and Lok index grade exhibited the highest diagnostic value in predicting OS in patients without cirrhosis and those undergoing surgery.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Percutaneous Radiofrequency Ablation for Intermediate-Stage Hepatocellular Carcinoma
    Kariyama, Kazuya
    Wakuta, Akiko
    Nishimura, Mamoru
    Kishida, Masayuki
    Oonishi, Ayano
    Ohyama, Atsushi
    Nouso, Kazuhiro
    Kudo, Masatoshi
    ONCOLOGY, 2015, 89 : 19 - 26
  • [22] EVOLUTIONARY LEARNING DERIVED MODELS FOR PREDICTING SURVIVAL OF PATIENTS WITH INTERMEDIATE STAGE HEPATOCELLULAR CARCINOMA UNDERGOING TRANSARTERIAL CHEMOEMBOLIZATION
    Lee, I-Cheng
    Chen, Ting-Chun
    Lee, Rheun-Chuan
    Ho, Shinn-Ying
    Huang, Yi Hsiang
    HEPATOLOGY, 2021, 74 : 642A - 642A
  • [23] COMPARISON OF NONINVASIVE LIVER RESERVE MODELS IN PREDICTION OF SURVIVAL IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
    Jaruvongvanich, Veeravich
    Sempokuya, Tomoki
    Wong, Linda
    GASTROENTEROLOGY, 2018, 154 (06) : S1241 - S1241
  • [24] Selecting an Optimal Staging System for Intermediate-Stage Hepatocellular Carcinoma: Comparison of 9 Currently Used Prognostic Models
    Zhang, Yong-Fa
    Shi, Ming
    Lu, Liang-He
    Wang, Lu
    Guo, Rong-Ping
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2021, 8 : 253 - 261
  • [25] Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma
    Tada, Toshifumi
    Kumada, Takashi
    Hiraoka, Atsushi
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Shimada, Noritomo
    Kawata, Kazuhito
    Tada, Fujimasa
    Ohama, Hideko
    Nouso, Kazuhiro
    Morishita, Asahiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Imai, Michitaka
    Kosaka, Hisashi
    Naganuma, Atsushi
    Matono, Tomomitsu
    Aoki, Tomoko
    Kuroda, Hidekatsu
    Yata, Yutaka
    Koizumi, Yohei
    Nakamura, Shinichiro
    Kaibori, Masaki
    Iijima, Hiroko
    Hiasa, Yoichi
    Kudo, Masatoshi
    LIVER INTERNATIONAL, 2024, 44 (01) : 113 - 124
  • [26] New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization
    Kim, Jin Hyoung
    Shim, Ju Hyun
    Lee, Han Chu
    Sung, Kyu-Bo
    Ko, Heung-Kyu
    Ko, Gi-young
    Gwon, Dong Il
    Kim, Jong Woo
    Lim, Yung-Suk
    Park, Seong Ho
    LIVER INTERNATIONAL, 2017, 37 (12) : 1861 - 1868
  • [27] Comparison of transcatheter arterial chemoembolization and transcatheter arterial chemotherapy infusion for patients with intermediate-stage hepatocellular carcinoma
    Nishikawa, Hiroki
    Osaki, Yukio
    Kita, Ryuichi
    Kimura, Toru
    Ohara, Yoshiaki
    Takeda, Haruhiko
    Sakamoto, Azusa
    Saito, Sumio
    Nishijima, Norihiro
    Nasu, Akihiro
    Komekado, Hideyuki
    Nishiguchi, Shuhei
    ONCOLOGY REPORTS, 2014, 31 (01) : 65 - 72
  • [28] A Prognostic Score for Patients with Intermediate-Stage Hepatocellular Carcinoma Treated with Transarterial Chemoembolization
    Ogasawara, Sadahisa
    Chiba, Tetsuhiro
    Ooka, Yoshihiko
    Kanogawa, Naoya
    Motoyama, Tenyu
    Suzuki, Eiichiro
    Tawada, Akinobu
    Azemoto, Ryosaku
    Shinozaki, Masami
    Yoshikawa, Masaharu
    Yokosuka, Osamu
    PLOS ONE, 2015, 10 (04):
  • [29] Efficacy of Sorafenib in Intermediate-Stage Hepatocellular Carcinoma Patients Refractory to Transarterial Chemoembolization
    Ogasawara, Sadahisa
    Chiba, Tetsuhiro
    Ooka, Yoshihiko
    Kanogawa, Naoya
    Motoyama, Tenyu
    Suzuki, Eiichiro
    Tawada, Akinobu
    Kanai, Fumihiko
    Yoshikawa, Masaharu
    Yokosuka, Osamu
    ONCOLOGY, 2014, 87 (06) : 330 - 341
  • [30] A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation
    Jia-yan Ni
    Zhu-ting Fang
    Hong-liang Sun
    Chao An
    Zhi-mei Huang
    Tian-qi Zhang
    Xiong-ying Jiang
    Yao-ting Chen
    Lin-feng Xu
    Jin-hua Huang
    European Radiology, 2020, 30 : 2377 - 2390